EUVIMEDEUVIMED entdecken
Crossref

Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy

Taisei Keitoku iD, Nobuharu Tamaki iD, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Shun Ishido, Michiko Yamada, Tsubasa Nobusawa und 13 weitere

Journal of Viral Hepatitis · 2023

DOI: 10.1111/jvh.13805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Taisei Keitoku und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The number of patients with fatty liver has been increasing worldwide; however, the significance of fatty liver in patients with chronic hepatitis B who are receiving nucleic acid analog (NA) therapy remains unclear. Thus, we aimed to determine whether fatty liver affects the development of hepatocellular carcinoma (HCC) in patients receiving NA therapy. This study included 445 patients who received NA therapy, and the development of HCC was investigated. The primary outcome was the association between fatty liver and HCC development. During a mean follow‐up period of 7.4 years, 46 patients (10.3%) developed HCC. No significant difference in the cumulative incidence of HCC was observed between patients with fatty liver and those without ( p = 0.17). Multivariable analysis for age, gender, platelet count, alanine aminotransferase level at 1 year following NA therapy, and fatty liver revealed that the presence of fatty liver was not a significant factor for HCC development (hazard ratio [HR]: 0.96, 95% confidence interval [CI]: 0.5–1.9). In another multivariable analysis for advanced fibrosis, gender, and fatty liver, advanced fibrosis was found to be a significant factor for HCC development (HR: 9.50, 95% CI: 5.1–18) but not fatty liver (HR: 0.90, 95% CI: 0.5–1.7). In conclusion, in patients with chronic hepatitis B who received NA therapy, advanced fibrosis was found to be an important risk factor for HCC development but not fatty liver, suggesting the importance of providing treatment before the progression of liver fibrosis regardless of the presence of fatty liver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicFatty LiverNucleic AcidsHumansRisk FactorsLiver CirrhosisAntiviral AgentsRetrospective Studies

Stichwörter der Autor:innen

advanced fibrosischronic hepatitis Bfatty liverhepatocellular carcinoma (HCC)nucleic acid analog

Substanzen

Nucleic AcidsAntiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

ORCID-Profile: Taisei Keitoku, Nobuharu Tamaki, Yasuhiro Asahina

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Keitoku, T., Tamaki, N., Kurosaki, M., Inada, K., Kirino, S., Uchihara, N., Suzuki, K., Tanaka, Y., Miyamoto, H., Ishido, S., Yamada, M., Nobusawa, T., Matsumoto, H., Higuchi, M., Takaura, K., Tanaka, S., Maeyashiki, C., Kaneko, S., Yasui, Y., …, & Izumi, N. (2023). Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13805

Vancouver

Keitoku T, Tamaki N, Kurosaki M, Inada K, Kirino S, Uchihara N, et al. Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13805

BibTeX
@article{Keitoku2023,
  author = {Keitoku, Taisei and Tamaki, Nobuharu and Kurosaki, Masayuki and Inada, Kento and Kirino, Sakura and Uchihara, Naoki and Suzuki, Keito and Tanaka, Yuki and Miyamoto, Haruka and Ishido, Shun and Yamada, Michiko and Nobusawa, Tsubasa and Matsumoto, Hiroaki and Higuchi, Mayu and Takaura, Kenta and Tanaka, Shohei and Maeyashiki, Chiaki and Kaneko, Shun and Yasui, Yutaka and Takahashi, Yuka and Tsuchiya, Kaoru and Nakanishi, Hiroyuki and Asahina, Yasuhiro and Okamoto, Ryuichi and Izumi, Namiki},
  title = {Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  doi = {10.1111/jvh.13805}
}
Kostenlos starten →